This post was originally published on this site Prostate cancer’s incidence and deadliness has declined or stabilized in much of the world in recent years, with the greatest decrease in risk evident in the U.S., a study reports. These findings were presented at the recent 2019 American Association for Cancer Research (AACR) Annual Meeting, which took…
This post was originally published on this site Some 87 buildings, landmarks, and businesses in the U.S. and Canada turned purple April 13 in an attempt to help raise awareness about sarcoidosis during Sarcoidosis Awareness Month. The initiative is called “Illuminate the Night: Shine a Light on Sarcoidosis,” and was begun by the nonprofit Foundation…
This post was originally published on this site Lynparza (olaparib) tablets have been approved by the European Commission as a standalone treatment for adults with a subset of locally advanced or metastatic breast cancer. The decision follows a recommendation by the Committee for Medicinal Products for Human Use (an arm of the European Medicines Agency), making…
This post was originally published on this site Myriad Genetics has submitted the first part of a premarket approval application with the U.S. Food and Drug Administration for myChoice HRD CDx, a diagnostic test designed to identify ovarian cancer patients more likely to benefit from treatment with the PARP inhibitor Zejula (niraparib). Premarket approval is the FDA’s…
This post was originally published on this site The Italian Medicines Agency has approved a first-in-human clinical trial testing MolMed’s investigational CAR T-cell product, CD44v6, for the treatment of acute myeloid leukemia and multiple myeloma, the company announced. The Phase 1/2 trial will be conducted at two clinical centers in Italy — the San Raffaele Hospital in…
This post was originally published on this site Long-term use of oral contraceptives protects women from the most lethal types of ovarian cancers, a large multi-center study has found. The study, “Oral contraceptive use and risk of highly fatal ovarian cancer: Evidence from the Ovarian Cancer Association Consortium,” was recently presented at the 2019 American…
This post was originally published on this site Janssen has submitted an application to Japanese authorities seeking the approval of Darzalex (daratumumab) — in combination with standard Revlimid (lenalidomide) and dexamethasone — for the treatment of newly diagnosed multiple myeloma patients ineligible for high-dose chemotherapy and stem cell transplant. The supplemental new drug application, which will be considered under priority review, is based on data from…
This post was originally published on this site While a significant proportion of non-Hodgkin’s lymphoma survivors suffer from severe fatigue, the type of initial treatment and Rituxan (rituxumab) use did not influence this outcome, a new study shows. Instead, severe fatigue was found to be correlated with increased age, obesity, and the presence of other comorbidities.…
This post was originally published on this site I have been a follicular lymphoma patient since 2008. One of the strangest things about this disease is the kind of “in-between-ness” that it can put some patients into. You’re not really cured, but you’re not really sick, either. (Terrilyn McCormick writes about this very well.) You…
This post was originally published on this site Early results from the ATALANTE-1 Phase 3 trial indicate that Tedopi benefits people with advanced non-small cell lung cancer (NSCLC) who failed to respond to prior checkpoint inhibitor therapy, OSE Immunotherapeutics reported. Three enrolled patients responded positively to third-line treatment with Tedopi, either achieving a partial reduction…
